Synopsis of recent research by authors named "Antoni Rimola"
Recent research by Antoni Rimola has focused primarily on the effectiveness and safety of direct-acting antivirals (DAAs) for treating hepatitis C virus (HCV) recurrence in liver transplant recipients, particularly those coinfected with HIV, demonstrating promising outcomes in this population.
His studies also investigate the underlying molecular pathways of subclinical inflammatory lesions in long-term liver transplant recipients, highlighting the complexities of post-transplant complications and the need for better understanding of allograft damage.
Additionally, Rimola's work includes evaluating the role of biomarkers in predicting acute rejection in liver transplant patients, along with exploring innovative preservation techniques to mitigate liver ischemia-reperfusion injury, showcasing a multi-faceted approach to improve transplantation outcomes.
